UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703

Nucleic acid therapeutics, 2015-06, Vol.25 (3), p.130-140

2015

Volltextzugriff (PDF)

Genuine Immunomodulation With dSLIM

Molecular therapy. Nucleic acids, 2014-06, Vol.3 (6), p.e170-e170, Article e170

2014

Volltextzugriff (PDF)

Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine

PloS one, 2014-07, Vol.9 (7), p.e101715-e101715

2014

Volltextzugriff (PDF)

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist

Molecular therapy. Oncolytics, 2016, Vol.3 (C), p.15023-15023, Article 15023

2016

Volltextzugriff (PDF)

Cavrotolimod, a Nanoparticle Toll-like Receptor 9 Agonist, Inhibits Tumor Growth and Alters Immune Cell Composition in Mouse Models of Skin Cancer

ACS applied nano materials, 2023-02, Vol.6 (4), p.2682-2696

2023

Volltextzugriff (PDF)

Peripheral Non-Viral MIDGE Vector-Driven Delivery of β-Endorphin in Inflammatory Pain

Molecular pain, 2009-12, Vol.5 (1), p.72-72

2009

Volltextzugriff (PDF)

A Novel Minimal-Size Vector (MIDGE) Improves Transgene Expression in Colon Carcinoma Cells and Avoids Transfection of Undesired DNA

Molecular therapy, 2001-05, Vol.3 (5), p.793-800

2001

Volltextzugriff (PDF)

Immunization of Cats against Feline Immunodeficiency Virus (FIV) Infection by Using Minimalistic Immunogenic Defined Gene Expression Vector Vaccines Expressing FIV gp140 Alone or with Feline Interleukin-12 (IL-12), IL-16, or a CpG Motif

Journal of Virology, 2000-11, Vol.74 (22), p.10447-10457

2000

Volltextzugriff (PDF)

740. The TLR9 Agonist EnanDIM® - Evaluation of New Enantiomeric Oligonucleotides for Cancer Immunotherapy In Vitro and In Vivo

Molecular therapy, 2016-05, Vol.24, p.S292-S292

2016

Volltextzugriff (PDF)

Minimal Size MIDGE Vectors Improve Transgene Expression In Vivo

In vivo (Athens), 2007-01, Vol.21 (1), p.17-23

2007

Volltextzugriff (PDF)

Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours

European journal of cancer (1990), 2015-01, Vol.51 (2), p.146-156

2015

Volltextzugriff (PDF)

Abstract 2565: Conformation overrides base sequence - insights from a novel class TLR-9 agonists

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2565-2565

2014

Volltextzugriff (PDF)

Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis

Science translational medicine, 2014-04, Vol.6 (234), p.234ra56

2014

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic data of the immunotherapeutic TLR-9 agonist MGN1703 from healthy volunteers and cancer patients

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e14015-e14015

2015

Volltextzugriff (PDF)

Abstract 4558: Immunogenicity and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4558-4558

2017

Volltextzugriff (PDF)

MGN1703 - structure of agonist determines cellular responses to TLR9 activation

Molecular therapy, 2013-09, Vol.21 (9), p.e7-e7

2013

Volltextzugriff (PDF)

ITOC2 – 035. The immunotherapeutic TLR-9 agonist MGN1703 – Pharmacokinetic and pharmacodynamic data from healthy volunteers and cancer patients

European journal of cancer (1990), 2015-03, Vol.51, p.S12-S12

2015

Volltextzugriff (PDF)

213. Treatment with MGN1601 Induces Immune Responses Against Tumor Associated Antigens in Patients with Renal Cell Carcinoma

Molecular therapy, 2015-05, Vol.23, p.S84-S84

2015

Volltextzugriff (PDF)

Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.74-74

2018

Volltextzugriff (PDF)

Abstract B196: Live attenuated oral Salmonella platform for effective targeting of multiple tumor-associated epitopes and PD-L1

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B196-B196

2018

Volltextzugriff (PDF)

Immune response induced by a linear DNA vector: Influence of dose, formulation and route of injection

Vaccine, 2010-05, Vol.28 (21), p.3642-3649

2010

Volltextzugriff (PDF)

Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e15590-e15590

2014

Volltextzugriff (PDF)

ASET study: Long-term follow-up data of patients with metastatic renal cell carcinoma treated with MGN1601

Journal of clinical oncology, 2014-02, Vol.32 (4_suppl), p.LBA399-LBA399

2014

Volltextzugriff (PDF)

Identification of biomarkers for overall survival of patients with metastatic renal cell carcinoma treated with MGN1601

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.468-468

2013

Volltextzugriff (PDF)

Abstract A035: Pharmacokinetics and pharmacodynamics of the immunotherapeutic TLR-9 agonist MGN1703 – conclusions by comparison of data from clinical trials with healthy volunteers and cancer patients

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.A035-A035

2016

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(42)
Buchkapitel
(1)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(19)
Animals
(13)
Mice
(11)
Female
(9)
Medicine, Research & Experimental
(9)
Research & Experimental Medicine
(9)
Mice, Inbred Balb C
(8)
Biological And Medical Sciences
(7)
Genetic Vectors
(6)
Immunology
(6)
Male
(6)
Vaccines, Dna - Immunology
(6)
Deoxyribonucleic Acid
(5)
Dna
(5)
Gene Expression
(5)
Humans
(5)
Medical Sciences
(5)
Plasmids
(5)
Hepatitis B Surface Antigens - Immunology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703

Genuine Immunomodulation With dSLIM

Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist

Cavrotolimod, a Nanoparticle Toll-like Receptor 9 Agonist, Inhibits Tumor Growth and Alters Immune Cell Composition in Mouse Models of Skin Cancer

Peripheral Non-Viral MIDGE Vector-Driven Delivery of β-Endorphin in Inflammatory Pain

A Novel Minimal-Size Vector (MIDGE) Improves Transgene Expression in Colon Carcinoma Cells and Avoids Transfection of Undesired DNA

Immunization of Cats against Feline Immunodeficiency Virus (FIV) Infection by Using Minimalistic Immunogenic Defined Gene Expression Vector Vaccines Expressing FIV gp140 Alone or with Feline Interleukin-12 (IL-12), IL-16, or a CpG Motif

740. The TLR9 Agonist EnanDIM® - Evaluation of New Enantiomeric Oligonucleotides for Cancer Immunotherapy In Vitro and In Vivo

Minimal Size MIDGE Vectors Improve Transgene Expression In Vivo

Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours

Abstract 2565: Conformation overrides base sequence - insights from a novel class TLR-9 agonists

Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis

Pharmacokinetic and pharmacodynamic data of the immunotherapeutic TLR-9 agonist MGN1703 from healthy volunteers and cancer patients

Abstract 4558: Immunogenicity and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m

MGN1703 - structure of agonist determines cellular responses to TLR9 activation

ITOC2 – 035. The immunotherapeutic TLR-9 agonist MGN1703 – Pharmacokinetic and pharmacodynamic data from healthy volunteers and cancer patients

213. Treatment with MGN1601 Induces Immune Responses Against Tumor Associated Antigens in Patients with Renal Cell Carcinoma

Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1

Abstract B196: Live attenuated oral Salmonella platform for effective targeting of multiple tumor-associated epitopes and PD-L1

Immune response induced by a linear DNA vector: Influence of dose, formulation and route of injection

Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study

ASET study: Long-term follow-up data of patients with metastatic renal cell carcinoma treated with MGN1601

Identification of biomarkers for overall survival of patients with metastatic renal cell carcinoma treated with MGN1601

Abstract A035: Pharmacokinetics and pharmacodynamics of the immunotherapeutic TLR-9 agonist MGN1703 – conclusions by comparison of data from clinical trials with healthy volunteers and cancer patients

Suchergebnisse filtern